Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360® liquid biopsy test for clinical decision-making in advanced lung cancer at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, September 8-14, 2021.

New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit. Guardant Health's management is scheduled to participate in a fireside chat on Tuesday, August 10 at 4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company w

Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit

After the market close on Thursday, Guardant Health Inc (NASDAQ: GH) reported Q2 revenues increased 39% Y/Y to $92.1 million, beating the consensus of $84.61 million. Guardant's oncology testing revenue grew 42% to $72.6 million, driven primarily by a 54% increase in clinical testing revenue.

Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates

Guardant Health's (GH) CEO Helmy Eltoukhy on Q2 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadership structure to support the Company's strategic objectives for future growth. Under this structure, Helmy Eltoukhy, CEO, and AmirAli Talasaz, President, will serve as co-CEOs of Guardant Health. Both Eltoukhy and Talasaz will continue to serve on the Board of Directors and Eltoukhy will assume the role of Chairman. In addition, Meghan Joyce, Chief Operatin

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2021. Recent Highlights Revenue of $92.1 million for the second quarter of 2021, an increase of 39% over the corresponding period of 2020 Reported 20,830 tests to clinical customers and 3,653 tests to bi

Guardant Health Reports Second Quarter 2021 Financial Results

Align Technology

Nano-X Imaging

Pfizer

There's both rhyme and reason for checking out these four stocks.

Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline

SPRINGFIELD, Mo. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Fight Colorectal Cancer (Fight CRC), the nation's leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back to routine colorectal cancer screening. The award, called “Back to Screening Award for Research Advocacy Excellen

Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic

SEOUL, Souh Korea, July 19, 2021 /PRNewswire/ -- Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The deal, which includes the investment made by Guardant Health and also a groundbreaking collaboration between a liquid biopsy company and a medical AI startup, is intended to help reshape and innovate the precision oncology landscape.

AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 5, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The web

Guardant Health to Report Second Quarter Financial Results on August 5, 2021

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Guardant360 Response™ test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA (ctDNA) levels to provide oncologists an early indication of a patient's response to treatment. The Guardant360 TissueNext™ test, th

Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Please replace the release dated May 19, 2021 with the following corrected version due to a change in the fourth paragraph. The updated release reads: GUARDANT HEALTH PRESENTS DATA AT 2021 ASCO ANNUAL MEETING SHOWING UTILITY OF LIQUID BIOPSY IN EARLY- AND LATE-STAGE CANCERS Data from 20 abstracts demonstrate value of company's blood tests across the continuum of cancer care, including: screening, therapy selection, residual and recurrent disease detection,

CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the company's new Chief Commercial Officer for its oncology business, effective June 8, 2021. Chris brings significant experience successfully building and managing pharmaceutical and biotechnology brands through all stages of commercialization, which will be invaluable as the company's oncology portfolio expands to cover advanced a

Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer

Investing in a company operating in an industry tailwind usually leads to significant profits.

Guardant Health: A Stalwart With 20% Upside

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its LUNAR-2 blood test is a highly sensitive test that can detect colorectal cancer (CRC) in early-stage cancer patients. This largest ever cohort continues to demonstrate the performance and robustness of the LUNAR-2 assay.1,2 Today, it is estimated that only 68% of adults, 50 years

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx test as the first and only liquid biopsy companion diagnostic for tumor mutation profiling, or comprehensive genomic profiling, to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who harbor the KRAS G12C mutation and may benefit from LUMAKRAS™ (sotorasib), an FDA-approved KRASG12C inhibitor

Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading statements Natera has made about its own products and the performance of Guardant Health's new oncology test, Guardant Reveal™. Guardant Health asked the federal court in San Francisco, California for an injunction preventing Natera from continuin

Guardant Health Files Lawsuit Against Natera for Misleading Oncologists

Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 0 1 Somewhat Bullish 1 1 0 2 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for Guardant Health. The company has an average price target of $170.0 with a high of $190.00 and a low of $145.00.

Where Guardant Health Stands With Analysts

Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.

With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble?

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as the first and only companion diagnostic for Janssen Biotech, Inc.'s (Janssen's) RYBREVANT™ (amivantamab-vmjw). The Guardant360 CDx test will be used for tumor mutation profiling, or comprehensive genomic profiling, to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who

Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen's RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), to present data demonstrating the use of the company's proprietary blood tests to advance precision oncology, including cancer screening, detecting residual or recurrent disease in early-stage cancer, and treatment selection and treatment response monitoring in advanced cancer. Data, from 20 abstracts, will be presented along with other leading medical institutions and pharmaceutical companies, during the 2021 American S

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

Exact Sciences

Pacific Biosciences of California

Falling costs are ushering in a new era of screening for a dreaded disease.

3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming

Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 1 0 0 2 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 7 analysts have offered 12-month price targets for Guardant Health. The company has an average price target of $177.14 with a high of $190.00 and a low of $160.00.

What 7 Analyst Ratings Have To Say About Guardant Health

Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q1 2021 Results - Earnings Call Transcript

News for Guardant Health Inc Stock (GH)